InsidersTradesSigma
Zoetis Inc. Stock: price and directors' dealings · United States · SEC (Form 4)
Track the Zoetis Inc. stock price and the full insider trade history of the company, a listed equity based in United States. Shares trade on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Zoetis Inc. has recorded 223 reports. Market capitalisation: €31.6bn. The latest transaction was reported on 13 May 2026 (Acquisition). Among the most active insiders: Lagano Roxanne. All data is accessible without an account.
223
Insider Decl.
0
Thresholds
€1m
4 ops.
Buy Volume
€16m
35 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Zoetis Inc. Buy (bullish), based on 17 analysts. Average price target: US$118.29.
50Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 1,906 of 25,484 companies
76.4
score / 100
Value72
Quality81
FCF yld7.2%
Earn yld8.5%
EV/EBITDA10.0x
ROE68%
Gross mgn72%
Net mgn28%
Debt/EBITDA2.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 13 May 2026
Declarations223 total
6,650 shares@ US$75.390.0014% mcap50.0% of flowCommon StockSEC:0001628280-26-034643:0
Ideal exit: 7 Feb 2027 (T+270)
6,650 shares@ US$75.390.0014% mcap50.0% of flowCommon StockSEC:0001628280-26-034643
Ideal exit: 7 Feb 2027 (T+270)
2,000 shares@ US$75.8750.0004% mcap50.0% of flowCommon StockSEC:0001628280-26-034642
Ideal exit: 7 Feb 2027 (T+270)
2,000 shares@ US$75.8750.0004% mcap50.0% of flowCommon StockSEC:0001628280-26-034642:0
Ideal exit: 7 Feb 2027 (T+270)
381 sharesCommon StockSEC:0001628280-26-006891:0
200 shares@ US$127.4216.5% of flowCommon StockSEC:0001628280-26-006891:1
398 sharesCommon StockSEC:0001628280-26-006891:2
209 shares@ US$127.4217.3% of flowCommon StockSEC:0001628280-26-006891:3
1,601 sharesCommon StockSEC:0001555280-25-000223:0
1,830 shares0Common StockSEC:0001555280-25-000220:0
1,451 sharesCommon StockSEC:0001555280-25-000174:0
1,506 sharesCommon StockSEC:0001555280-25-000170:0
1,210 shares@ US$166.1415.3% of flowCommon StockSEC:0001555280-25-000151:0
326 shares@ US$170.000.6% of flowCommon StockSEC:0001555280-25-000152:0
382 shares@ US$46.090.4% of flowCommon StockSEC:0001555280-25-000106:0
1,843 shares0Common StockSEC:0001555280-25-000104:0
393 sharesCommon StockSEC:0001555280-25-000089:0
214 sharesCommon StockSEC:0001555280-25-000086:0
1,225 sharesCommon StockSEC:0001555280-25-000090:0
1,389 sharesCommon StockSEC:0001555280-25-000087:0
663 sharesCommon StockSEC:0001555280-25-000092:0
597 sharesCommon StockSEC:0001555280-25-000095:0
1,225 sharesCommon StockSEC:0001555280-25-000082:0
6,135 sharesCommon StockSEC:0001555280-25-000080:0
1,225 sharesCommon StockSEC:0001555280-25-000093:0
25 of 223 declarations
About Zoetis Inc.
Zoetis Inc. (ticker: ZTS) is a U.S.-listed healthcare company traded on the NYSE and one of the global leaders in animal health. Headquartered in Parsippany, New Jersey, United States, Zoetis traces its roots to Pfizer’s animal health business and became an independent public company following its IPO in 2013. Today, the company describes itself as the world’s leading animal health company and operates in more than 100 countries, with a commercial footprint spanning both the U.S. and international markets. ([zoetis.com](https://www.zoetis.com/our-company/our-story/about-us)) Zoetis discovers, develops, manufactures and commercializes a broad portfolio of vaccines, medicines, biopharmaceuticals, diagnostics and digital solutions for companion animals and livestock. Its business model is built around what it calls the “continuum of care,” covering prevention, detection and treatment. From an equity analysis perspective, the company stands out for its recurring revenue profile, premium brands, and science-led innovation across parasiticides, dermatology, pain management and livestock health. Key products and franchises include Simparica Trio, Apoquel, Librela, Cytopoint, and multiple cattle, swine and poultry offerings. ([zoetis.com](https://www.zoetis.com/our-company/our-story/about-us)) Competitive positioning is supported by Zoetis’ scale, global distribution, deep customer relationships and strong R&D engine. Management emphasizes an integrated strategy combining innovation, manufacturing excellence and commercial execution. In 2024, Zoetis reported 11% operational revenue growth and said it expanded its product portfolio through more than 100 geographic expansions and nearly 20 product enhancements. It also completed the divestiture of its medicated feed additive portfolio, certain water-soluble products and related assets on October 31, 2024, sharpening its focus on higher-priority segments. ([zoetis.com](https://www.zoetis.com/_assets/pdf/corporate/zoetis-2024-annual-report.pdf)) Recent corporate developments reinforce the company’s growth narrative. Throughout 2025, Zoetis announced several regulatory and product milestones, including approvals and label updates tied to major brands such as Simparica Trio, Librela and Lenivia. In its February 2026 full-year update, the company reported 2025 revenue of $9.5 billion and raised its 2026 outlook, signaling continued momentum in a structurally attractive animal-health market. For investors, Zoetis remains a quality defensive healthcare name with global reach, a strong innovation pipeline and a diversified mix between companion animal and livestock businesses. ([news.zoetis.com](https://news.zoetis.com/press-releases/press-release-details/2026/Zoetis-Reports-Fourth-Quarter-and-Full-Year-2025-Results/default.aspx))
